[Portrait de Louis] Vasseur, athlète : [photographie de presse] / [Agence Rol]

Référence bibliographique : Rol, 58010

Julliard [portrait du boxeur] : [photographie de presse] / [Agence Rol]

Référence bibliographique : Rol, 58119

[Portrait de] M. Clémenceau : [photographie de presse] / [Agence Rol]

Référence bibliographique : Rol, 57648

[Portrait de] M. Paul Deschanel : [photographie de presse] / [Agence Rol]

Référence bibliographique : Rol, 57647

[Portrait de l'] amiral Horthy : [photographie de presse] / [Agence Rol]

Référence bibliographique : Rol, 58161

[Portrait du] capitaine [George Hubert] Wilkins qui va en avion au pôle sud accompagnant l'expédition impériale antarctique : [photographie de presse] / [Agence Rol]

Référence bibliographique : Rol, 58114

[Portrait de femme] : [photographie de presse] / [Agence Rol]

Référence bibliographique : Rol, 57252

[Portrait de] M. Clémenceau : [photographie de presse] / [Agence Rol]

Référence bibliographique : Rol, 57622

Julliard [portrait du boxeur] : [photographie de presse] / [Agence Rol]

Référence bibliographique : Rol, 58118

[Portrait de] M. [Hugh] Wallace, ambassadeur des U.S. [Etats-Unis] à Paris : [photographie de presse] / [Agence Rol]

Référence bibliographique : Rol, 58172

Dumas [portrait du boxeur, salle Cré] : [photographie de presse] / [Agence Rol]

Référence bibliographique : Rol, 57119

Repression of flagellar genes in exponential phase by CsgD and CpxR, two crucial modulators of Escherichia coli biofilm formation.

Escherichia coli adapts its lifestyle to the variations of environmental growth conditions, swapping between swimming motility or biofilm formation. The stationary-phase sigma factor RpoS is an important regulator of this switch, since it stimulates adhesion and represses flagellar biosynthesis. By measuring the dynamics of gene expression, we show that RpoS inhibits the transcription of the flagellar sigma factor, FliA, in exponential growth phase. RpoS also partially controls the expression of CsgD and CpxR, two transcription factors important for bacterial adhesion. We demonstrate that these two regulators repress the transcription of fliA, flgM, and tar and that this regulation is dependent on the growth medium. CsgD binds to the flgM and fliA promoters around their -10 promoter element, strongly suggesting direct repression. We show that CsgD and CpxR also affect the expression of other known modulators of cell motility. We propose an updated structure of the regulatory network controlling the choice between adhesion and motility.

Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma.

Purpose: Invasion and migration are key processes of glioblastoma and are tightly linked to tumor recurrence. Integrin inhibition using cilengitide has shown synergy with chemotherapy and radiotherapy in vitro and promising activity in recurrent glioblastoma. This multicenter, phase I/IIa study investigated the efficacy and safety of cilengitide in combination with standard chemoradiotherapy in newly diagnosed glioblastoma. Patients and Methods: Patients (age >= 18 to >= 70 years) were treated with cilengitide (500 mg) administered twice weekly intravenously in addition to standard radiotherapy with concomitant and adjuvant temozolomide. Treatment was continued until disease progression or for up to 35 weeks. The primary end point was progression-free survival (PFS) at 6 months. Results: Fifty-two patients ( median age, 57 years; 62% male) were included. Six- and 12-month PFS rates were 69% (95% CI, 54% to 80%) and 33% ( 95% CI, 21% to 46%). Median PFS was 8 months ( 95% CI, 6.0 to 10.7 months). Twelve- and 24-month overall survival ( OS) rates were 68% ( 95% CI, 53% to 79%) and 35% ( 95% CI, 22% to 48%). Median OS was 16.1 months ( 95% CI, 13.1 to 23.2 months). PFS and OS were longer in patients with tumors with O-6-methylguanine-DNA methyltransferase (MGMT) promoter methylation (13.4 and 23.2 months) versus those without MGMT promoter methylation (3.4 and 13.1 months). The combination of cilengitide with temozolomide and radiotherapy was well tolerated, with no additional toxicity. No pharmacokinetic interactions between temozolomide and cilengitide were identified. Conclusion: Compared with historical controls, the addition of concomitant and adjuvant cilengitide to standard chemoradiotherapy demonstrated promising activity in patients with glioblastoma with MGMT promoter methylation. J Clin Oncol 28:2712-2718. (C) 2010 by American Society of Clinical Oncology

Portrait de Gillot : [estampe] / gravé par Jean Aubert ; d'après Watteau

Référence bibliographique : Dacier et Vuaflart, n. d.